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CLINICAL REPORT

Guidance for the Clinician in Rendering Pediatric Care

Diagnosis and Management of Infantile
Hemangioma: Executive Summary
David H. Darrow, MD, DDS, Arin K. Greene, MD, Anthony J. Mancini, MD, Amy J. Nopper, MD, the SECTION ON DERMATOLOGY,
SECTION ON OTOLARYNGOLOGY–HEAD & NECK SURGERY, AND SECTION ON PLASTIC SURGERY

INTRODUCTION
Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike
other tumors, they have the capacity to involute after proliferation, often
leading primary care providers to assume they will resolve without
intervention or consequence. However, a subset of IHs may be associated with
complications, resulting in pain, functional impairment, or permanent
disﬁgurement. As a result, the primary care provider is often called on to decide
which lesions should be referred for early consultation with a specialist.
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The guidance in this statement does not indicate an exclusive course
of treatment or serve as a standard of medical care. Variations, taking
into account individual circumstances, may be appropriate.
All clinical reports from the American Academy of Pediatrics
automatically expire 5 years after publication unless reafﬁrmed,
revised, or retired at or before that time.
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This document provides a summary of the guidance contained in the
clinical report “Diagnosis and Management of Infantile Hemangioma,”
published concurrently in the online version of Pediatrics (Pediatrics.
2015;136[4]:e1060–e1104, available at: www.pediatrics.org/content/
136/4/e1060.full). The report is uniquely based on input from the many
specialties involved in the treatment of IH. Its purpose is to update the
pediatric community about recent discoveries in IH pathogenesis, clinical
associations, and treatment and to provide a knowledge base and
framework for clinical decision-making in the management of IH.

NOMENCLATURE
• Infantile hemangiomas (IHs) are vascular neoplasms characterized by
abnormal proliferation of endothelial cells and aberrant blood vessel
architecture. In contrast, vascular malformations are structural anomalies and inborn errors of vascular morphogenesis. The latter include
capillary malformations (port wine stains), venous malformations,
lymphatic malformations (formerly known as lymphangiomas or cystic
hygromas), and arteriovenous malformations.
• Congenital hemangiomas are biologically and behaviorally distinct from
IHs. They are fully grown at birth and present as 2 varieties: rapidly
involuting (RICH) and noninvoluting (NICH).
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• Pyogenic granuloma, or lobular capillary hemangioma, is a reactive
proliferative vascular lesion. Although classiﬁed with the vascular
neoplasms and often misdiagnosed as IH, pyogenic granuloma is distinct
in its clinical appearance and behavior.
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• Lesions diagnosed as “cavernous
hemangiomas” are usually, in fact,
deep IHs or venous malformations.
• Kasabach–Merritt phenomenon (a
consumptive coagulopathy) is not
associated with IH but rather with
other vascular neoplasms (kaposiform hemangioendothelioma and
tufted angioma).
EPIDEMIOLOGY
• The incidence of IH is estimated at
approximately 5% of infants, and
the female/male ratio ranges from
1.4:1 to 3:1.
• IH risk factors include white race,
prematurity, low birth weight, advanced maternal age, multiple gestation pregnancy, placenta previa, and
preeclampsia. Other risk factors may
include in utero diagnostic procedures (chorionic villus sampling and
amniocentesis), use of fertility drugs
or erythropoietin, breech presentation, and being ﬁrst born.
PATHOGENESIS AND HISTOPATHOLOGY
• The pathogenesis of IH remains to
be clearly elucidated. Both intrinsic
factors (such as angiogenic and
vasculogenic factors) and extrinsic
factors (including tissue hypoxia
and developmental ﬁeld disturbances) probably contribute to
development of IH.
• Endothelial progenitor cells may
develop into IH from clonal expansion, resulting in vasculogenesis;
alternatively, fetal progenitor cells
arising from disruption of the placenta during gestation or birth may
give rise to these tumors.
• A unifying theory suggests that IH
results from aberrant proliferation
and differentiation of a pluripotent
progenitor cell, which migrates to
locations in which growth of
placenta-like tissue is favorable.
• Proliferative IHs histologically reveal well-deﬁned masses of capillaries lined by plump endothelial
cells, arranged in lobules, often
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with enlarged draining veins. Involuting IHs reveal ﬁbrofatty
stroma, residual “ghost” vessels,
mast cells, and apoptotic bodies.

• Immunohistochemical staining of
IH is positive for glucose transporter 1 (GLUT1), CD31, CD34,
factor VIII–related antigen, and
others; GLUT1 is the most useful
and widely used marker for the
diagnosis of IH.
CLINICAL PRESENTATION
• IHs usually appear before 4 weeks
of age and complete most of their
growth by 5 months of age, although the proliferative phase may
continue up to 12 months of age.
Deep IHs tend to appear later and
grow somewhat longer. The involution phase usually begins between 6 and 12 months of age, and
the majority of regression occurs
before 4 years of age. As IHs involute, they ﬂatten and shrink, with
fading of their color.
• Up to 70% of IHs leave behind residual skin changes, including telangiectasia, ﬁbrofatty tissue,
redundant skin, atrophy, dyspigmentation, and scar (especially in
lesions with history of past
ulceration).
• Premonitory ﬁndings in early IH
include localized blanching of skin
and macular telangiectatic
erythema.
• During the proliferative phase, IHs
may be classiﬁed based on their
depth, as follows (Fig 1):
• Superﬁcial IH: Surface appears
red, and there is little or no discernible subcutaneous
component.
• Deep IH: Surface appears blue or
ﬂesh-colored, and the tumor
resides deep below the skin
surface.
• Combined IH: both superﬁcial
and deep components.
• Abortive (arrested growth, minimal growth, nascent) IH (Fig 2)
presents as a telangiectatic patch
Downloaded from by guest on February 7, 2017

that does not uniformly
proliferate.

• IHs may also be classiﬁed according to their anatomic conﬁguration:
• Localized (focal) IH: discrete
lesions, arise from single focal
point
• Segmental IH (Fig 3): larger
lesions, usually plaque-like, covering regions probably determined by neuroectodermal
placodes
• Indeterminate IH: cannot deﬁnitively be categorized as localized or segmental
• Multifocal IH: focal lesions occurring at more than 1 anatomic
site; may be a marker for hepatic
IH when 5 or more cutaneous
lesions are present
• Segmental IH may be associated
with extracutaneous
manifestations.
• A small subset of children with IH
present with congenital anomalies
recognized as clinical associations.
These include:
• PHACE, which is a congenital
vasculopathy with features of
Posterior fossa defects, Hemangiomas, cerebrovascular Arterial
anomalies, Cardiovascular
anomalies including Coarctation
of the aorta, and Eye anomalies.
In PHACE, the IH is large and
segmental, characteristically located on the face, scalp, or neck.
• LUMBAR, which refers to Lower
body IH and other cutaneous
defects, Urogenital anomalies
and Ulceration, Myelopathy, Bony
deformities, Anorectal malformations, Arterial anomalies, and
Renal anomalies. The associated
IHs are usually segmental lumbosacral or anogenital lesions.
LUMBAR, also described under
the acronyms “SACRAL” and
“PELVIS,” may be thought of
as the “lower half of the body”
variant of PHACE.
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IMAGING
• Imaging of IH is not usually
necessary.
• Imaging may be necessary when
the diagnosis is uncertain, when
evaluation of extent is necessary,
when the IH is a possible marker of
PHACE or LUMBAR syndrome, or
when response to therapy must be
monitored.

FIGURE 1
Cutaneous IHs can be classiﬁed based on their depth. A, Superﬁcial IHs are visible only at the skin
surface and may be focal (as shown here) or segmental. B, Deep IHs have no surface involvement. C,
Mixed, or compound, IHs have both superﬁcial and deep components.

COMPLICATIONS

• Auditory impairment

• A minority of IH (up to 24% referred to pediatric dermatologists)
may develop function-threatening
or life-threatening complications,
including:
• Ulceration: most common IH
complication, occurring in 16%
of patients in 1 large series; risk
factors include larger lesions,
segmental IH, and distribution in
the head, neck, perioral, and
perineal or perianal locations

• Nasal deformities
• Congestive heart failure: may
occur with large IHs, as a result
of arteriovenous shunting

• Bleeding
• Visual impairment: associations
include ptosis, amblyopia,
astigmatism
• Feeding impairment: most often
associated with IH on the lips or
in the aerodigestive tract

• Airway obstruction: risk of airway IH increased with facial IH
in the “beard” distribution
• Hypothyroidism: may be associated with diffuse hepatic IH;
caused by excess production of
type 3 iodothyronine deiodinase
• Segmental IHs are much more
likely to develop complications
(usually ulceration) than localized
IH.
• Facial IHs are complicated more
frequently than nonfacial IHs.

• When imaging of IH is performed,
ultrasound is the preferred modality for diagnosis, whereas MRI
is better to assess extent of the
lesion.
CLINICAL APPROACH TO IH
• The indications for intervention for
IH include:
• Emergency treatment of potentially life-threatening
complications
• Urgent treatment of existing or
imminent functional impairment,
pain, or bleeding
• Evaluation to identify important
structural anomalies potentially
associated with IH
• Elective treatment to reduce the
likelihood of long-term or permanent disﬁgurement
• There is no algorithm to determine
the most appropriate modality and
timing of intervention for a given
IH. Factors affecting this choice
include:
• Age of the patient
• Growth phase of the lesion
• Location and size of the lesion
• Degree of skin involvement
• Severity of complications and
urgency of intervention
• Potential for adverse psychosocial consequences
• Parental preference
• Physician experience

FIGURE 2
Abortive IHs are macular, telangiectatic patches
that have failed to fully proliferate.
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MANAGEMENT OF ULCERATED IH
FIGURE 3
Segmental IH of the face.
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• Treatment recommendations for
ulcerated IH are based largely on
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expert opinion; high-quality studies
of interventions and evidencebased guidelines are lacking.

treatment of IH showed effectiveness when dosed at 3.4 mg/
kg per day for 6 months.

• Ulcerated IH management is focused on wound care, pain control,
controlling IH growth, and prevention and treatment of secondary
infection. Vigilant wound care and
use of barrier ointments or dressings, as well as topical antibiotics,
are generally considered ﬁrst-line
therapy for ulcerated IH.

• Contraindications to propranolol
therapy include cardiogenic
shock, sinus bradycardia, hypotension, heart block greater than
ﬁrst degree, heart failure, asthma
or reactive airway disease, and
known hypersensitivity to the
drug. Special precautions have
been suggested for children with
PHACE syndrome who have
high-risk intracranial vascular
anomalies.

• For ulcerated IH with suboptimal
response to conservative topical
care, additional medical or surgical
interventions may be needed.
There is growing evidence that
propranolol may be effective in
treating severe ulcerated IH. In
addition, pulsed-dye laser may also
be helpful in treating persistent
ulceration. Rarely, surgical intervention may be indicated in recalcitrant ulcerations.
MEDICAL THERAPY FOR IH
• Systemic corticosteroids were the
mainstay of therapy from the
1960s until a 2008 report of
serendipitous improvement of IH
in infants treated with b-blocker
therapy (propranolol).
• b-blocker therapy:
• The mechanism of action of propranolol, a nonselective blocker
of b-adrenergic receptors that
has been used to treat cardiac
disorders, is not fully understood. Proposed mechanisms
of action include vasoconstriction, inhibition of angiogenesis,
downregulation of matrix metalloproteinases and interleukin-6,
regulation of the renin–angiotensin system, and inhibition of
nitric oxide production.
• An oral formulation of propranolol (Hemangeol [Pierre
Fabre, Castres, France]) for
treatment of IH received approval from the US Food and
Drug Administration in March
2014. A large 2015 randomized
controlled trial of Hemangeol in
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• Recommendations for pretreatment assessment and the
optimal setting for therapy initiation continue to evolve and vary
between clinicians. A complete
history and physical examination
with special attention to the
cardiac and pulmonary systems
aids in assessing a child’s candidacy
for propranolol initiation.
Although some clinicians obtain
pretreatment electrocardiogram
or cardiology consultation before
starting propranolol, the value of
such screening in patients with
an unremarkable cardiac history
and examination is uncertain.
• A consensus report recommends
initiation of propranolol therapy in
a clinic setting with cardiovascular
monitoring hourly for 2 hours
after initiation and recommends
repeat monitoring for dosage
increases of .0.5 mg/kg per day
for infants .8 weeks of age. Inpatient initiation of propranolol is
considered for infants ,8 weeks
of age or infants with postconceptual age ,48 weeks and for
infants with decreased social support or increased risk factors.
• Recommended administration of
propranolol is 1 to 3.4 mg/kg per
day divided into 2 or 3 doses.
Duration of therapy is usually
until 8 to 12 months of age, or
between 3 and 12 months of
therapy, depending on age of
initiation and clinical response.
Downloaded from by guest on February 7, 2017

Rebound growth after discontinuation of therapy is reported in
5% to 25% of patients; therefore,
some clinicians wean propranolol over a number of weeks
or months.

• Common adverse effects of propranolol include sleep disturbance, cold hands and feet,
diarrhea, and bronchial hyperreactivity. Rare adverse effects include bradycardia and
hypotension, which are generally
asymptomatic, and severe hypoglycemia, which may be associated with decreased
responsiveness or seizures.
• Precautions that may reduce the
risk of hypoglycemia with propranolol therapy include administration of medication after
feeding; holding doses when the
patient is ill with decreased oral
intake, vomiting, or diarrhea; and
avoiding prolonged intervals of
longer than 6 hours between
feedings.
• A number of case reports and
case series have reported successful use of topical timolol, a bblocker used to treat glaucoma,
in the treatment of uncomplicated superﬁcial IH. Timolol 0.5% gel-forming solution
has less systemic absorption
than timolol in solution.
• Corticosteroid therapy:
• For patients with contraindications or inadequate response to propranolol therapy,
corticosteroids may be an effective treatment alternative. Most
studies support dosing with oral
prednisolone or prednisone at 2
to 3 mg/kg per day given in
a single morning dose. Several
months of therapy is generally
necessary; treatment is more
likely to be successful when initiated during IH proliferation.
• Long-term corticosteroid therapy
may be associated with many
adverse effects, including irritability, sleep disturbance, gastric
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irritation, hypertension, immunosuppression, hypothalamic–pituitary–adrenal axis
suppression, linear growth deceleration, and cushingoid facies.
These adverse effects are more
frequently seen with higher
doses and prolonged therapy and
tend to be reversible. Periodic
monitoring for potential toxicity,
especially blood pressure elevation and decreased rate of
growth, is recommended.

• Intralesional steroid injections
are often effective in treating
small, bulky, well-localized IH
lesions. However, although adverse systemic effects have been
reported rarely, intralesional
steroids may be systemically
absorbed, especially when given
in larger doses or multiple
injections, and optimal dosing
and safety proﬁle are not well
studied. As a result, this modality
is no longer considered ﬁrst-line
therapy for most IHs. Highpotency topical steroids have
been reported as effective in the
treatment of small superﬁcial IH,
although their use is largely being replaced by treatment with
topical b-blockers.
• Other medical therapies:
• Medications other than b-blockers and corticosteroids may have
efﬁcacy in treating IH, but their
utility is limited by their safety
proﬁle. Interferon-a appeared to
be a promising treatment option
in the 1980s and early 1990s,
but studies showing signiﬁcant
neurotoxicity have generally
precluded this treatment modality for IH.
LASER TREATMENT OF IH
• Laser treatment of IH may be useful in treating early nonproliferating superﬁcial lesions,
salvaging critical skin, controlling
ulceration, and treating persisting
postinvolution telangiectasia. Laser
therapy may also be used as
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a component of multimodal
therapy.

• The pulsed-dye laser is used most
commonly, because its light is
preferentially absorbed by
hemoglobin.
• Some studies suggest that the use
of the pulsed-dye laser on proliferating and segmental IHs may
lead to ulceration. Atrophic scarring and hypopigmentation are also
potential complications of laser use
in IH.
SURGICAL THERAPY FOR IH
• Resection of a proliferating IH
generally is not recommended, because younger patients are at
greater risk of anesthetic morbidity,
blood loss, and iatrogenic injury
than those who undergo operative
intervention later in childhood.
Indications for excising a hemangioma during infancy include failure
of other therapy for a critical IH,
a focal lesion in a favorable location, or elective surgery leaving
a scar that would be the same if the
lesion were removed after
involution.
• Delaying surgery until after infancy
allows the lesion time to involute,
becoming smaller and less vascular.
Consequently, the procedure is
safer, and often the patient has
a shorter scar and a higher likelihood of a favorable outcome.
However, most IHs do not improve
signiﬁcantly beyond 4 years of age,
and surgery by this age corrects the
deformity before self-esteem and
long-term memory are well
established.
• Because hemangiomas usually expand the skin, after they are removed the wound usually can be
reconstructed by linear closure.
Skin grafts and local ﬂaps are rarely
needed.
• Because IH is benign, the entire
lesion does not need to be extirpated. The goal is to improve the
appearance of the child, and
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subtotal excision often is performed intentionally.

• For circular lesions located on the
face, the length of the scar can be
minimized by circular excision and
purse-string closure. This procedure also minimizes distortion of
surrounding structures and may
require a second stage to convert
a circular scar into a line.
IHs WITH SPECIAL ANATOMIC
CONCERNS
• IHs involving the eyelids can deform the cornea and obstruct the
visual axis, causing astigmatism,
strabismus, or amblyopia. Early
evaluation by a pediatric ophthalmologist and early intervention
may reduce the risk of complications and sequelae.
• Propranolol has largely supplanted
intralesional steroid injection for
treating problematic IHs of the
upper eyelid because the risk of
blindness from embolization of the
retinal artery. However, intralesional steroids are an alternative
for refractory lesions. Topical
b-blockers may be useful for intraocular IHs.
• IHs of the airway may occur in
isolation, but patients with large
cutaneous lesions involving the
lower face and neck (the so-called
“beard” distribution) are at greater
risk. Most lesions are subglottic,
and patients so affected can have
biphasic stridor and barky cough
that are often mistaken for croup.
Operative endoscopy is generally
necessary to identify the lesions
and assess their extent. Symptomatic lesions are generally treated
with propranolol, but patients who
do not respond rapidly may be
candidates for dilation, intralesional corticosteroid injection, or
partial resection. Open resection
has become less commonly indicated since introduction of propranolol therapy for IH.
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• Early management of nasal tip IH
using some combination of pharmacotherapy and laser reduces the
likelihood of long-term deformity
from skin expansion and atrophy
and of injury to the underlying
cartilage. Reconstruction of involuted nasal tip IHs is often necessary even with aggressive early
intervention and includes excision
of the lesion, reconstruction of the
cartilaginous framework, and excision and redraping of the skin.
• IHs involving the lips and perineum, especially segmental lesions,
have a higher risk of ulceration;
early pharmacotherapy may be effective in avoiding this complication. Reduction of friction on
perineal IHs using topical lubrication with or without a barrier
dressing may help prevent
ulceration.
• IHs located within the vermilion
area of the lip can be removed with
a transverse mucosal incision, although some deep lesions are
best approached through the
vermilion–cutaneous border. Bulkier
lesions that cause lengthening of
the lip and those that cross the
vermilion–cutaneous border are best
addressed with a wedge excision.
Eversion of the lower lip can be
corrected by excision of a mucosal
strip, and correction of inversion
may require a lyophilized dermal
implant or dermal graft.
• The liver is the most common location of visceral hemangiomas:
• Infants with $5 cutaneous
hemangiomas are at greater risk
of hepatic lesions and are candidates for screening by
ultrasonography.
• Liver hemangiomas can be focal,
multifocal, or diffuse. Focal
lesions are actually RICHs that
are fully grown at birth and
rapidly involute over the ﬁrst
year of life. Multifocal and diffuse
lesions are true infantile
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hemangiomas and often coexist
with cutaneous lesions. Symptomatic multifocal and diffuse
lesions can be treated with systemic pharmacotherapy.

• Infants with signiﬁcant multifocal or diffuse hemangiomas
should undergo thyroid hormone
screening because the tumor can
deactivate thyroid hormone.
Hormone replacement may be
necessary.
• Diffuse lesions may present with
hepatomegaly and cause abdominal compartment syndrome.
CONCLUSIONS
Although many IHs can be observed
without treatment, others will clearly
beneﬁt from medical or surgical
intervention. When complications are
likely or the threshold for
intervention is uncertain, referral to
an experienced specialist or
a multidisciplinary vascular anomaly
center may be advantageous. It is
important for providers of pediatric
care to keep abreast of advances in IH
management as continued research
leads to pathogenesis-directed
therapeutic options and as the types
of intervention and their use evolve.
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